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Integrins are a family of cell surface receptors that mediate
cell–cell and cell–extracellular matrix adhesion in various cell
types including epithelial keratinocytes (Watt and Jones, 1993;
Larjava et al, 1996). These receptors are heterodimeric trans-
membrane glycoproteins composed of an alpha (a) and beta (b)
subunit. Currently 22 different a and eight b-subunits are known.
These subunits can variously combine to form more than 22
different cell surface receptors that have distinct ligand binding
specificities.
Normal skin and mucosal epithelium express several different
integrins. In normal epithelium, a6b4 integrin binds to laminin-5 of
the anchoring filaments and serves as an integral component of the
hemidesmosome (Stepp et al, 1990; Sonnenberg et al, 1991). a2b1
and a3b1 integrins are localized in basal epithelial cells. They are
known to be involved in cell–cell binding and binding of various
collagen types and laminin-5 respectively (Carter et al, 1990;
Staquet et al, 1990). A few integrins are generally absent from
normal epithelium. Basal keratinocytes do not normally express
avb3 and  avb6 integrins (Breuss et al, 1995; Haapasalmi et al,
1995). avb5 has been detected from the same areas of normal
buccal mucosa (Adams and Watt, 1991). On the other hand, it has
been also reported to be absent from normal gingival epithelium
(Larjava et al, 1993). avb6 is an exclusively epithelial integrin that
has been shown to bind to fibronectin and tenascin (Sheppard et al,
1990; Prieto et al, 1993). Its expression is restricted to only a few
locations in healthy adult tissues in humans (Breuss et al, 1993).
Expression of avb6 integrin is, however, induced during wound
healing and in squamous cell carcinoma (SCC) (Breuss et al, 1995;
Haapasalmi et al, 1996).
It is not known at which stage of transformation of oral epithe-
lial cells to SCC the expression of avb6 integrin begins. Epithelial
cells that are in the process of malignant transformation can be
found in some of the oral leukoplakia lesions. Studies indicate that
malignant transformation of leukoplakia occurs over a range from
about 1% to as high as 17%, averaging 4–5% (Gupta et al, 1980;
Silverman et al, 1984). We investigated, therefore, whether epithe-
lial cells in oral leukoplakia express avb6 integrin and whether this
change could be associated with the malignant transformation.
MATERIALS AND METHODS
Tissues
Oral biopsy specimens of 29 cases of leukoplakia (11 from the
gingiva, nine from the buccal or alveolar mucosa and nine from
the tongue mucosa), eight of lichen planus (buccal mucosa), and
11 of SCCs were included in this study. From the leukoplakia
patients, 11 were either current or past smokers, nine were non-
smokers and for nine cases smoking history was unavailable. The
diagnosis of leukoplakia and lichen planus were based on clinical
and histological criteria. The leukoplakia tissue specimens were
histologically graded (dysplasia, hyperplasia, hyperkeratosis,
inflammation, etc.) by two pathologists independently (Tables 1
and 2). In case of differing opinion, biopsy specimen was re-exam-
ined and discussed until a consensus was reached. For controls, 11
normal oral specimens (six from the buccal mucosa and five from
the gingiva), three chronically inflamed and five hyperplastic
gingival tissue biopsies were originally taken during surgical
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procedures necessary for treatment. The hyperplastic lesions were
either idiopathic (one case), drug-induced, e.g. amlodipine bensyl-
ate (one case), or caused by irritation by dentures (three cases).
Seven-day-old human mucosal wound specimens were obtained
from a collection stored in the laboratory (Larjava et al, 1993)
(Tables 1 and 2). All samples were obtained from the University of
British Columbia, Canada, British Columbia Cancer Agency,
Canada, or the University of Oulu, Oulu, Finland.
The follow-up data of all the leukoplakia patients were collected
from British Columbia Cancer Agency, where the original leuko-
plakia tissue specimens were collected. The progression or
improvement of the disease in the long-term follow-up was
assessed by a clinician who was unaware of all the staining results.
The most recent follow-up information for each patient (1–4 years
after the diagnosis) was collected from 28 of the 29 patients. The
clinical and pathological data from the time of the biopsy of each
patient was compared to the data of the last two recent visits of the
patients. Patients were followed at least once a year after the
original biopsy. If the conditions had progressed (either in size, or
transformation to SCC), it was recorded as a disease progression.
If none of the above conditions was applicable, then the disease
was recorded as either no change, improved, or resolved accord-
ingly. These results were then used to calculate the sensitivity and
specificity of the avb6 integrin staining as a possible prognostic
Table 1 Expression of different integrins, fibronectin and tenascin in oral precancers and squamous cell carcinoma
Staining intensity
n b1 b3 b4 b5 b6 av FN TN
Leukoplakia 29
Dysplasia 22
Mild 15 ++ – ++ – –/+ –/+ +++ +++
Moderate 6 ++ – ++ – –/+ –/+ +++ +++
Severe 1 ++ – ++ – –/+ –/+ +++ +++
Other types 7 ++ – ++ – –/+ –/+ +++ +++
Lichen planus 8
All types 8 ++ – ++ – + + ND ND
Squamous cell carcinoma
Grade I 6 ++ ND ++ ND ++ ++ ND ND
Grade II 3 ++ ND ++ ND ++ ++ ND ND
Grade III 2 ++ ND ++ ND ++ ++ ND ND
Controls 22
Normal mucosa 11 ++ – ++ – – – +++ +++
7-day-old wound 3 ++ ND ++ ND ++ ++ +++ +++
Hyperplasia 5 ++ – ++ – – – ND ND
Chronic inflammation 3 ++ – ++ – – – ND ND
Leukoplakia was classified to dysplasia or others (see Table 2). (–) No staining; (–/+) some specimens positive, some negative (see Table
4); (+) positive cells; (++) intense staining in basal cell layer; (+++) strong staining in basal cell layer, sometimes suprabasal cells and/or
connective tissue. FN, fibronectin; TN, tenascin; ND, not determined.
Table 2 Immunolocalization of av and avb6 integrin in oral lesions
Clinical diagnosis Pathological av b6 INF°
diagnosis
Leukoplakia HK, PK 2/2 2/2 2
Leukoplakia HP 3/4 3/4 2
Leukoplakia AT 1/1 1/1 3
Leukoplakia DP 6/22 6/22 2
• mild 3/15 3/15 2
• moderate 2/6 2/6 2
• severe 1/1 1/1 2
Reticular lichen planus lichen planus 7/8 7/8 3
Squamous cell carcinoma SCC 10/11 4/5 0–2
Normal mucosa normal 0/11 0/11 0
Hyperplasia HP 0/5 0/5 0–3
Periodontitis CINF 0/5 0/5 3
Healing wounds 7-day-old wound 3/3 3/3 1
Numbers in the first two columns indicate the number of positive/total specimens examined in each case. HK,
hyperkeratosis; PK, parakeratosis; HP, hyperplasia; AT, atypia; DP, dysplasia; CIFN, chronic inflammation; SCC, squamous
cell carcinoma. Degree of inflammation (INF°) was visually graded as from 0 to 3 (from no inflammatory cells to abundant
infiltration). The prevalence of av and avb6 integrin expression in leukoplakia, SCC and lichen planus is significantly
increased compared to controls (ANOVA, P < 0.05).British Journal of Cancer (2000) 82(7), 1433–1440
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test for disease progression. The most common treatments for the
lesions were topical vitamin C cream (41% of patients) and beta
carotene (31% of the patients).
Antibodies
Monoclonal antibody to the b1 integrin (mAb 13) subunit was a
generous gift of Dr Kenneth Yamada, NIDR/NIH, and antibody to
the avb6 integrin complex (E7P6) was a kind gift of Dr Dean
Sheppard of Lung Biology Center, University of San Francisco.
Monoclonal antibody to av integrin (L230) (Houghton et al, 1982)
was purified from cell culture supernatant of hybridoma cells
grown in our laboratory, and the antibodies against b4 integrin
(AA3; monoclonal), fibronectin and tenascin were purchased from
Gibco-BRL (Gaithersburg, MD, USA). The monoclonal anti-
bodies to avb3 integrin complex (mAb 1976), and avb5 integrin
complex (mAb 1961) were purchased from Chemicon (Temecula,
CA, USA).
Immunofluorescence
Frozen sections (5 mm) were placed on glass slides which were
treated with acetone containing 3-aminopropyl-triethoxy-silane
(Tespa; Sigma Chemical Co., St Louis, MO, USA), and fixed
briefly in chilled acetone (–20°C). Immunolocalization of inte-
grins was performed as described previously (Larjava et al, 1993).
Briefly, sections were washed with phosphate-buffered saline




















Figure 1 Immunolocalization of b1 and b4 integrins in normal (A, B), leukoplakia (C, D) and squamous cell carcinoma (E, F) respectively. E, epithelium;
CT, connective tissue; Bar = 100 mmChemical Co., St Louis, MO, USA) and incubated with optimally
diluted primary antibodies in PBS/BSA in a humid chamber
overnight. After rinsing, sections were incubated with affinity-
purified rhodamine-conjugated secondary antibodies (1:50,
Boehringer-Mannheim Biochemicals, Indianapolis, IN, USA) for
60 min. Sections were mounted using Krazy Glue (Borden Co.
Ltd). Tissue specimens were stained with the primary antibodies
as indicated (Table 1). Control stainings were performed using
non-immune antibody or secondary antibody alone. Samples were
examined using a Zeiss Axioskop 20 fluorescence microscope,
and photographed using an MC 80 Zeiss microscope camera.
The intensity of the stainings was graded visually using a +/–
scale. Specimens were classified as follows: (–) no staining was
seen; (–/+) some sections were positive, and some negative (see
Table 3); (+) some positive cells; (++) intense staining in the basal
cell layer; and (+++) strong antibody staining in basal cell layer,
sometimes suprabasal cells and/or connective tissue (stainings for
fibronectin and tenascin). Staining with antibodies to integrins b1
and b4, fibronectin and tenascin produced uniform pattern in all
specimens studied. Staining with antibodies recognizing av and
avb6 integrins produced more variable results since some speci-
mens were negative and some positive (–/+). Staining was consid-
ered positive and the intensity was scored if at least one rete ridge
was reacted with the antibody.
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Figure 2 Immunolocalization of avb6 integrin complex and av integrin subunit in normal (A, B), leukoplakia (C, D) and squamous cell carcinoma (E, F)
respectively. Rete ridges are demonstrated using the dotted lines (A, B). The arrow heads point to the areas of cells that are reactive with antibodies to avb6
integrin complex (C) and av (D) integrin subunit. E, epithelium; CT, connective tissue; Bar = 100 mmBritish Journal of Cancer (2000) 82(7), 1433–1440
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RESULTS
Localization of integrins and their binding molecules in
normal mucosa
The integrins of b1 and b4 families were present in all normal
tissues (Figure 1 and Table 1). b1 integrins were localized at the
periphery of the basal cells and in the connective tissue and
endothelial cells (Figure 1A). b4 integrin was localized at the basal
surface of the basal keratinocytes (Figure 1B). Antibodies against
either avb6 or av integrin were not reactive in normal specimens
(Figure 2 A, B). Fibronectin and tenascin were both present in the
connective tissue, especially in areas close to the basement
membrane zone (not shown). Antibodies against b3 or b5 integrins
were not reactive in normal oral mucosa (not shown) (Table 1).
Localization of integrins and their binding molecules in
leukoplakia
In leukoplakia, expression of b1 and b4 integrins resembled that of
normal tissues (Figure 1 C, D). In some specimens, the expression
of b1 was found in several cell layers but often appeared somewhat
reduced in the intensity (not shown). Forty-one per cent (12/29) of
all the leukoplakia specimens expressed avb6 integrin. Twenty-
seven per cent (6/22) of the dysplasia specimens expressed avb6
integrin, while 86% (6/7) of the other types (hyperkeratosis, hyper-
plasia and atypia) expressed it (Table 2). The expression was in
most cases confined to the basal keratinocytes at the tip of the rete
ridges. No or very little suprabasal expression was observed.
Localization using antibodies to av or avb6 complex showed a
similar distribution pattern (Figure 2 C, D). Epithelial cells of
inflammatory, drug-induced or idiopathic hyperplasia or chronic
inflammatory lesions (periodontitis) did not express avb6 integrin
(Tables 1 and 2). None of the leukoplakia sections were reactive
with b3 or b5 integrin antibodies (Table 1). Both fibronectin and
tenascin were expressed underneath the oral epithelium of the
leukoplakic tissues, at the area near the basement membrane zone
similar to normal oral mucosa (Figure 3 A, B). Seven-day-old
wounds were stained with antibodies to av and avb6 integrins as
positive controls. In 7-day-old wounds avb6 integrin was present
around basal cells covering the newly formed granulating tissue
confirming our previous results (Haapasalmi et al, 1996) (Tables 1
and 2).
Localization of integrins in lichen planus
The staining pattern of lichen planus specimens with antibodies
against b1 and b4 integrin was similar to that of the normal tissues
(Figure 4 A, B) except in some of the tissue specimens the staining
was discontinuous in the basal cell layer, and patchy losses were
also observed. In some areas of lichen planus, b4 integrin was
localized around the basal cells as we have observed before
(Haapalainen et al, 1995). avb6 integrin was very strongly present
around keratinocytes in basal and suprabasal cell layers of 85%
(7/8) of all the lichen planus specimens studied. The staining
pattern using antibodies to avb6 complex paralleled that of av,
however, the staining using av integrin antibody appeared to be
relatively stronger (Figure 5 A, B). avb6 integrin was often seen in
addition to the basal cell layer in several suprabasal cell layers
(Figures 4C and 5B). Antibodies to b3 and b5 integrins were not
reactive in lichen planus specimens (Figure 5 C, D).
Localization of integrins in SCC
Several cell layers of squamous cell carcinoma lesions expressed
b1 and b4 integrins (Figure 1 E, F). The staining pattern of these
two integrins in the malignant tissues was more dominant and
observed in more cell layers than that in the normal tissues.
Antibodies to av and avb6 integrin complex were also strongly
reactive in SCC (Figure 2 E, F). Tumour cells in several cell layers
appeared to express these integrins. Eighty per cent (4/5) of the
sections were positive when avb6 integrin antibody was used, and
90% (10/11) were positive when stained with av integrin antibody
only.
Follow-up data of the leukoplakia patients
The charts of all the leukoplakia patients were reviewed and their
status at last follow-up to 1 year or more after the biopsies was
studied. All the patients whose diseases had progressed expressed
avb6 integrin. The five tissue specimens that expressed av b6 inte-
grin and showed disease progression represented two moderate
dysplasias, and one severe dysplasia, one atypia which all
progressed to SCC. One mild dysplasia progressed to recurrent
dysplasia. Four leukoplakia specimens that were avb6 integrin-








Figure 3 Immunolocalization of fibronectin (A) and tenascin (B) in
leukoplakia. E, epithelium; CT, connective tissue; Bar = 100 mmBritish Journal of Cancer (2000) 82(8), 1433–1440
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lesions (n = 18) that did not initially express avb6 integrin
progressed. Smoking history did not clearly correlate with the
expression of avb6 integrin or disease progression. It should be
kept in mind, however, that only a limited number of specimens
from patients with positive smoking history were studied.
DISCUSSION
The purpose of our study was to clarify whether epithelial cells in
oral leukoplakia express avb6 integrin and whether this expression
could be associated to malignant transformation of the lesions.
Oral leukoplakia is a premalignant lesion that has potential to
undergo malignant transformation (WHO, 1997). As high as 17%
of the lesions may progress to malignant lesions of the oral cavity
(Gupta et al, 1980; Silverman et al, 1984). avb6 is an exclusively
epithelial integrin that is able to bind fibronectin and tenascin in
the extracellular matrix (Sheppard et al, 1990; Prieto et al, 1993).
Expression of avb6 integrin is induced during tumorigenesis and
epithelial repair (Breuss et al, 1995; Clark et al, 1996; Haapasalmi
et al, 1996). It has previously been shown that avb6 integrin is
strongly expressed in SCCs of oral cavity (Breuss et al, 1995;
Jones et al, 1997). Many of the cigarette smokers who develop
lung cancer, express avb6 integrin in the proximal airway epithe-
lium (Liebert et al, 1994).
In our study, 40% of the leukoplakia specimens expressed avb6
integrin. We were also able to show that those lesions that
progressed during the follow-up period were avb6-positive
although the material was relatively small. None of the initially
avb6-negative leukoplakia progressed over time suggesting that a
negative immunofluorescence finding for avb6 integrin could be
used as a marker for non-progressive lesions. Since the portion of
leukoplakia specimens that expressed avb6 is much higher than the
reported rate of malignancy (maximally 17%), many of the posi-
tive lesions are not likely to be progressive. Several oncoproteins
such as p53 and p16 have been tested as possible markers for
malignant progression (Gallo et al, 1997). No single marker seems
to be able to predict malignant transformation (Gallo et al, 1997).
It remains to be shown whether the expression of avb6 integrin







Figure 4 Immunolocalization of b1 (A), b4 (B) and avb6 (C) integrins in parallel sections of oral lichen planus. E, epithelium; CT, connective tissue;











Figure 5 Immunolocalization of av (A), avb6 (B), b3 (C) and b5 (D) integrins in lichen planus. E, epithelium; CT, connective tissue; Bar = 100 mmcombined with other possible markers could be valuable in
predicting malignant transformation of oral leukoplakia.
In addition to malignant transformation, there must be alterna-
tive explanations why so many leukoplakia specimens express
avb6 integrin. One possible explanation is mechanical irritation or
trauma that may be associated with leukoplakia, in which case
induced avb6 integrin expression could be associated to epithelial
repair. Subclinical inflammation is also reported to be associated
with the induction of avb6 integrin expression in the lungs (Breuss
et al, 1995). Epithelial cells in chronically inflamed oral mucosa
appear  avb6-negative, however, suggesting that inflammation
alone is not sufficient to induce avb6 integrin expression
(Haapasalmi et al, 1995). Furthermore, we observed that epithelial
cells in most of the lichen planus specimens also expressed avb6
integrin. The frequency of malignant change in lichen planus
ranges from 0.4 to 3.3% (Scully et al, 1998). It is likely therefore
that expression of avb6 integrin in lichen has no association with
malignant transformation. It is possible that the induced avb6 inte-
grin expression could be associated to certain type of inflamma-
tory reaction, such as predominance of lymphocytes in lichen
planus. Alternatively, epithelial cell phenotypes that express avb6
integrin may be altered and play a role of controlling epithelial
driven inflammation. Inactivation of b6 integrin gene causes infil-
tration of macrophages into the skin and accumulation of lympho-
cytes around conducting airways in the lungs (Huang et al, 1996).
Adding b6 integrin gene back to alveolar type II cells and bronchi-
olar epithelial cells in b6 knockout mice appears to reverse lung
inflammation, suggesting that avb6 integrin may have a down-
regulatory effect on pulmonary inflammation (Huang et al, 1998).
Interestingly, it has been recently reported that avb6 integrin can
bind and activate transforming growth factor b1 (TGF-b1) (Munger
et al, 1999). This activation mechanism may have implications in
cancer since overexpression of TGF-b1 by epithelial cells
enhances malignant progression rate and phenotype and induces
high incidence of particularly malignant fibroblastoid spindle cell
carcinomas (Cui et al, 1996).
It is likely that the induction of avb6 integrin could happen via
alternative routes in oral leukoplakia specimens. In some
specimens, this induction appears to be associated to the inflam-
matory reaction or tissue repair as discussed above. In the lesions
that progressed to SCC, the induction of avb6 integrin expression
is likely be linked to malignant transformation as a necessary but
not sufficient prerequisite. Most cell lines derived from squamous
cell carcinoma tumours express avb6 integrin (Koivisto et al,
2000). Colon carcinoma cell lines also frequently express avb6
integrin (Agrez et al, 1996). Heterologous expression of avb6
integrin in colon carcinoma cell line is associated to enhanced
tumour growth (Agrez et al, 1994) which effect appears to be
mediated through the cytoplasmic tail of b6 integrin. In addition to
its growth regulatory role, this unique cytoplasmic tail may also
regulate signalling of gelatinase B (Niu et al, 1998). It is possible,
therefore, that avb6 integrin could have multiple roles in malignant
transformation, including cell adhesion and migration, regulation
of cell growth and inflammation, and signalling of matrix
degradation.
In summary, 41% oral leukoplakia specimens express avb6 inte-
grin that could be associated to epithelial repair, inflammation and
malignant transformation. Expression of avb6 integrin appears to
be necessary but not sufficient for malignant transformation and it
may have multiple roles in tumour formation.
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